The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia

Leukemia and Lymphoma

Volumn 45, Issue 4, 2004, Pages 639-648

  Jing, Yongkui ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute promyelocytic leukemia; APL; PML RAR fusion protein; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CYTARABINE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRICHOSTATIN A; VORINOSTAT; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; LEUKEMIA REMISSION; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; TRANSCRIPTION REGULATION; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ARSENICALS; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; TRETINOIN;

EID: 1342266237     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001609933     Document Type: Review

References (131)

1. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. and Dejean, A. (1991) "The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR", Cell, 66, 675-684.
2. Kakizuka, A., Miller, W.H., Jr., Umesono, K., Warrell, R.P., Jr., Frankel, S.R., Murty, V.V., et al. (1991) "Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML", Cell, 66, 663-674.
3. Chen, Z., Brand, N.J., Chen, A., Chen, S.J., Tong, J.H., Wang, Z.Y., et al. (1993) "Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia", EMBO J., 12, 1161-1167.
4. Wells, R.A., Catzavelos, C. and Kamel Reid, S. (1997) "Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia", Nat. Genet., 17, 109-113.
5. Redner, R.L., Rush, E.A., Faas, S., Rudert, W.A. and Corey, S.J. (1996) "The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion", Blood, 87, 882-886.
6. Arnould, C., Philippe, C., Bourdon, V., Gr goire, M.J., Berger, R. and Jonveaux, P. (1999) "The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia", Hum. Mol. Genet., 8, 1741-1749.
7. He, L.Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P.G., Soares, V., et al. (1997) "Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice", Proc. Natl. Acad. Sci. USA, 94, 5302-5307.
8. Grisolano, J.L., Wesselschmidt, R.L., Pelicci, P.G. and Ley, T.J. (1997) "Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences", Blood, 89, 376-387.
9. He, L., Bhaumik, M., Tribioli, C., Rego, E.M., Ivins, S., Zelent, A. and Pandolfi, P.P. (2000) "Two critical hits for promyelocytic leukemia", Mol. Cell, 6, 1131-1134.
10. Pandolfi, P.P. (2001) "In vivo analysis of the molecular genetics of acute promyelocytic leukemia", Oncogene, 20, 5726-5735.
11. Pandolfi, P.P. (2001) "Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia", Hum. Mol. Genet., 10, 769-775.
12. Chang, K.S., Stass, S.A., Chu, D.T., Deaven, L.L., Trujillo, J.M. and Freireich, E.J. (1992) "Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation break-point in acute promyelocytic leukemia", Mol. Cell. Biol., 12, 800-810.
13. Biondi, A., Rambaldi, A., Pandolfi, P.P., Rossi, V., Giudici, G., Alcalay, M., et al. (1992) "Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction", Blood, 80, 492-497.
14. Pandolfi, P.P., Alcalay, M., Longo, L., Fagioli, M., Zangrilli, D., Grignani, F., et al. (1992) "Molecular genetics of the t(15;17) of acute promyelocytic leukemia (APPL)", Leukemia, 6(Suppl. 3), 120s-122s.
15. Gallagher, R.E., Willman, C.L., Slack, J.L., Andersen, J.W., Li, Y.P., Viswanatha, D., et al. (1997) "Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study", Blood, 90, 1656-1663.
16. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., et al. (1998) "Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia", Nature, 391, 815-818.
17. Perez, A., Kastner, P., Sethi, S., Lutz, Y., Reibel, C. and Chambon, P. (1993) "PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR", EMBO J., 12, 3171-3182.
18. Koken, M.H., Linares Cruz, G., Quignon, F., Viron, A., Chelbi Alix, M.K., Sobczak Thepot, J., et al. (1995) "The PML growth-suppressor has an altered expression in human oncogenesis", Oncogene, 10, 1315-1324.
19. Hong, S.H., David, G., Wong, C.W., Dejean, A. and Privalsky, M.L. (1997) "SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia", Proc. Natl. Acad. Sci. USA, 94, 9028-9033.
20. Lin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H., Jr. and Evans, R.M. (1998) "Role of the histone deacetylase complex in acute promyelocytic leukaemia", Nature, 391, 811-814.
21. Guidez, F., Ivins, S., Zhu, J., Soderstrom, M., Waxman, S. and Zelent, A. (1998) "Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia", Blood, 91, 2634-2642.
22. He, L.Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A. and Pandolfi, P.P. (1998) "Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL", Nat. Genet., 18, 126-135.
23. Melnick, A. and Licht, J.D. (1999) "Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia", Blood, 93, 3167-3215.
24. Lin, R.J. and Evans, R.M. (2000) "Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers", Mol. Cell, 5, 821-830.
25. Hauksdottir, H. and Privalsky, M.L. (2001) "DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia". Cell Growth Differ., 12, 85-98.
26. Piazza, F., Gurrieri, C. and Pandolfi, P.P. (2001) "The theory of APL", Oncogene, 20, 7216-7222.
27. Mistry, A.R., Pedersen, E.W., Solomon, E. and Grimwade, D. (2003) "The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease", Blood Rev., 17, 71-97.
28. Cunningham, I., Gee, T.S., Reich, L.M., Kempin, S.J., Naval, A.N. and Clarkson, B.D. (1989) "Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital", Blood, 73, 1116-1122.
29. Head, D., Kopecky, K.J., Weick, J., Files, J.C., Ryan, D., Foucar, K., et al. (1995) "Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia", Blood, 86, 1717-1728.
30. Degos, L., Dombret, H., Chomienne, C., Daniel, M.T., Miclea, J.M., Chastang, C., et al. (1995) "All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]", Blood, 85, 2643-2653.
31. Castaigne, S. and Degos, L. (1995) "[Treatment of acute promyelocytic leukemia by all trans retinoic acid]", C. R. Seances Soc. Biol. Fil., 189, 515-520.
32. Fenaux, P., Chomienne, C. and Degos, L. (2001) "All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia", Semin. Hematol., 38, 13-25.
33. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., et al. (1988) "Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia", Blood, 72, 567-572.
34. Castaigne, S., Chomienne, C., Daniel, M.T., Ballerini, P., Berger, R., Fenaux, P. and Degos, L. (1990) "All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]", Blood, 76, 1704-1709.
35. Warrell, R.P., Jr., Frankel, S.R., Miller, W.H., Jr., Scheinberg, D.A., Itri, L.M., Hittelman, W.N., et al. (1991) "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)", N. Engl. J. Med., 324, 1385-1393.
36. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., et al. (1999) "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group", Blood, 94, 1192-1200.
37. Warrell, R.P., Jr., Maslak, P., Eardley, A., Heller, G., Miller, W.H., Jr. and Frankel, S.R. (1994) "Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience", Leukemia, 8, 929-933.
38. Frankel, S.R., Eardley, A., Heller, G., Berman, E., Miller, W.H., Jr., Dmitrovsky, E. and Warrell, R.P., Jr. (1994) "All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study", Ann. Intern. Med., 120, 278-286.
39. Delva, L., Cornic, M., Balitrand, N., Guidez, F., Miclea, J.M., Delmer, A., et al. (1993) "Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells [see comments]", Blood, 82, 2175-2181.
40. Niu, C., Yan, H., Yu, T., Sun, H.P., Liu, J.X., Li, X.S., et al. (1999) "Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients", Blood, 94, 3315-3324.
41. Soignet, S.L., Maslak, P., Wang, Z.G., Jhanwar, S., Calleja, E., Dardashti, L.J., et al. (1998) "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", N. Engl. J. Med., 339, 1341-1348.
42. Zhang, P., Wang, S.Y. and Hu, X. (1996) "Arsenic trioxide treated 72 cases of acute promyelocytic leukemia", Chin. J. Hematol., 17, 58-61.
43. Huang, S.Y., Chang, C.S., Tang, J.L., Tien, H.F., Kuo, T.L., Huang, S.F., et al. (1998) "Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia", Br. J. Haematol., 103, 1092-1095.
44. Raelson, J.V., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., et al. (1996) "The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells", Blood, 88, 2826-2832.
45. Chomeinne, C., Balitrand, N., Ballerini, P., Castaigne, S., de The, H. and Degos, L. (1991) "All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells", J. Clin. Invest., 88, 2150-2154.
46. Chen, G.Q., Zhu, J., Shi, X.G., Ni, J.H., Zhong, H.J., Si, G.Y., et al. (1996) "In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins", Blood, 88, 1052-1061.
47. Zhu, J., Koken, M.H., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., et al. (1997) "Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia", Proc. Natl. Acad. Sci. USA, 94, 3978-3983.
48. Jing, Y., Wang, L., Xia, L.J., Chen, G.Q., Chen, Z., Miller, W.H. and Waxman, S. (2001) "Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo", Blood, 97, 264-269.
49. Lin, R.J., Sternsdorf, T., Tini, M. and Evans, R.M. (2001) "Transcriptional regulation in acute promyelocytic leukemia", Oncogene, 20, 7204-7215.
50. Guidez, F. and Zelent, A. (2001) "Role of nuclear receptor corepressors in leukemogenesis", Curr. Top. Microbiol. Immunol., 254, 165-185.
51. Zelent, A., Guidez, F., Melnick, A., Waxman, S. and Licht, J.D. (2001) "Translocations of the RARalpha gene in acute promyelocytic leukemia", Oncogene, 20, 7186-7203.
52. Miller, W.H.J. and Waxman, S. (2002) "Differentiation induction as a treatment for hematologic malignancies", Oncogene, 21, 3496-3506.
53. Benoit, G.R., Tong, J.H., Balajthy, Z. and Lanotte, M. (2001) "Exploring (novel) gene expression during retinoid-induced maturation and cell death of acute promyelocytic leukemia", Semin. Hematol., 38, 71-85.
54. Liu, T.X., Zhang, J.W., Tao, J., Zhang, R.B., Zhang, Q.H., Zhao, C.J., et al. (2000) "Gene Expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells", Blood, 96, 1496-1504.
55. Hughes, T.R., Mao, M., Jones, A.R., et al. (2001) "Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer", Nat. Biotechnol., 19, 342-347.
56. Morosetti, R., Park, D.J., Chumakov, A.M., Grillier, I., Shiohara, M., Gombart, A.F., et al. (1997) "A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation", Blood, 90, 2591-2600.
57. Chumakov, A.M., Grillier, I., Chumakova, E., Chih, D., Slater, J. and Koeffler, H.P. (1997) "Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor", Mol. Cell. Biol., 17, 1375-1386.
58. Park, D.J., Chumakov, A.M., Vuong, P.T., Chih, D.Y., Gombart, A.F., Miller, W.H.J. and Koeffler, H.P. (1999) "CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment", J. Clin. Invest., 103, 1399-1408.
59. Watanabe, N., Nakajima, H., Ikeda, Y. and Handa, M. (2000) "A critical role for CAAT-enhancer binding protein epsilon in cell cycle arrest and apoptosis during myeloid differentiation", Blood, 96, 284a.
60. Khanna-Gupta, A., Zibello, T., Lekstrom-Himes, J. and Berliner, N. (2000) "C/EBPE mediate myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut) in 32Dc13 cells", Blood, 96, 282a.
61. Truong, B.T., Lee, Y.J., Lodie, T.A., Park, D.J., Perrotti, D., Watanabe, N., et al. (2003) "CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia", Blood, 101, 1141-1148.
62. Duprez, E.A., Koch, H. and Tenen, D.G. (2001) "C/EBPbeta is an important target of PML/RARA during ATRA-induced differentiation of APL cells", Blood, 98, 833a.
63. Dyck, J.A., Maul, G.G., Miller, W.H., Jr., Chen, J.D., Kakizuka, A. and Evans, R.M. (1994) "A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein", Cell, 76, 333-343.
64. Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., et al. (1996) "Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway", Cancer Res., 56, 2945-2948.
65. Duprez, E., Lillehaug, J.R., Naoe, T. and Lanotte, M. (1996) "cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha", Oncogene, 12, 2451-2459.
66. Duprez, E., Lillehaug, J.R., Gaub, M.P. and Lanotte, M. (1996) "Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells", Oncogene, 12, 2443-2450.
67. Zhu, J., Gianni, M., Kopf, E., Honore, N., Chelbi-Alix, M., Koken, M., et al. (2000) "Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins", Proc. Natl. Acad. Sci. USA, 96, 14807-14812.
68. Nervi, C., Ferrara, F.F., Fanelli, M., Rippo, M.R., Tomassini, B., Ferrucci, P.F., et al. (1998) "Caspases Mediate Retinoic Acid-Induced Degradation of the Acute Promyelocytic Leukemia PML/RARalpha Fusion Protein", Blood, 92, 2244-2251.
69. Gianni, M., Koken, M.H., Chelbi-Alix, M.K., Benoit, G., Lanotte, M., Chen, Z. and de The, H. (1998) "Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells", Blood, 91, 4300-4310.
70. Fanelli, M., Nervi, C., Pelicci, G. and Gambacorti-Passerini, C. (1997) "Constitutive degradation of the PML/RARa protein is present in retinoic acid (RA)-resistant acute promyelocytic leukemia cells and involves the proteasome proteolytic pathway", Blood, 90(Suppl), 70a.
71. Idres, N., Benoit, G., Flexor, M.A., Lanotte, M. and Chabot, G.G. (2001) "Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites", Cancer Res., 61, 700-705.
72. Benoit, G., Altucci, L., Flexor, M., Ruchaud, S., Lillehaug, J., Raffelsberger, W., et al. (1999) "RAR-independent RXR signaling induces t(15;17) leukemia cell maturation", EMBO J., 18, 7011-7018.
73. Jing, Y., Xia, L., Lu, M. and Waxman, S. (2003) "The cleavage product ΔPML-RARa contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells", Oncogene, 22, 4083-4091.
74. Radomska, H.S., Huettner, C.S., Zhang, P., Cheng, T., Scadden, D.T. and Tenen, D.G. (1998) "CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors", Mol. Cell. Biol., 18, 4301-4314.
75. Lodie, T.A., Behre, G., Zhang, P., Pelicci, P.G. and Tenen, D.G. (1998) "Expression of the leukemic fusion protein, PML/RARa inhibits C/EBPalpha DNA binding and blocks granulocytic differentiation", Blood, 92, 211a.
76. Tenen, D.G. (2001) "Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia", Leukemia, 15, 688-689.
77. Dermime, S., Grignani, F., Clerici, M., Nervi, C., Sozzi, G., Talamo, G.P., et al. (1993) "Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein", Blood, 82, 1573-1577.
78. Dermime, S., Grignani, F., Rogaia, D., Liberatore, C., Marchesi, E. and Gambacorti Passerini, C. (1995) "Acute promyelocytic leukaemia cells resistant to retinoic acid show further perturbation of the RAR alpha signal transduction system", Leuk. Lymphoma, 16, 289-295.
79. Shao, W., Fanelli, M., Ferrara, F.F., Riccioni, R., Rosenauer, A., Davison, K., et al. (1998) "Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells [see comments]", J. Natl. Cancer Inst., 90, 124-133.
80. Grignani, F., Ferrucci, P.F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., et al. (1993) "The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells", Cell, 74, 423-431.
81. Ruchaud, S., Duprez, E., Gendron, M.C., Houge, G., Genieser, H.G., Jastorff, B., et al. (1994) "Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line", Proc. Natl. Acad. Sci. USA, 91, 8428-8432.
82. Doucas, V. and Evans, R.M. (1996) "The PML nuclear compartment and cancer", Biochim. Biophys. Acta, 1288, M25-M29.
83. Boddy, M.N., Duprez, E., Borden, K.L. and Freemont, P.S. (1997) "Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies", J. Cell. Sci., 110, 2197-2205.
84. Jing, Y., Xia, L. and Waxman, S. (2002) "Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia", Blood, 100, 1008-1013.
85. Gallagher, R.E. (2002) "Retinoic acid resistance in acute promyelocytic leukemia", Leukemia, 16, 1940-1958.
86. Roussel, M.J. and Lanotte, M. (2001) "Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes", Oncogene, 20, 7287-7291.
87. Kitamura, K., Kiyoi, H., Yoshida, H., Saito, H., Ohno, R. and Naoe, T. (1997) "Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia", Leukemia, 11, 1950-1956.
88. Shao, W., Benedetti, L., Lamph, W.W., Nervi, C. and Miller, W.H., Jr. (1997) "A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation", Blood, 89, 4282-4289.
89. Nason-Burchenal, K., Allopenna, J., Begue, A., Stehelin, D., Dmitrovsky, E. and Martin, P. (1998) "Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells", Blood, 92, 1758-1767.
90. Duprez, E., Benoit, G., Flexor, M., Lillehaug, J.R. and Lanotte, M. (2000) "A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities", Leukemia, 14, 255-261.
91. Takayama, N., Kizaki, M., Hida, T., Kinjo, K. and Ikeda, Y. (2001) "Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia", Exp. Hematol., 29, 864-872.
92. Ding, W., Li, Y.P., Nobile, L.M., Grills, G., Carrera, I., Paietta, E., et al. (1998) "Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy", Blood, 92, 1172-1183.
93. Imaizumi, M., Suzuki, H., Yoshinari, M., Sato, A., Saito, T., Sugawara, A., et al. (1998) "Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia", Blood, 92, 374-382.
94. Fanelli, M., Minucci, S., Gelmetti, V., Nervi, C., Gambacorti-Passerini, C. and Pelicci, P.G. (1999) "Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance", Blood, 93, 1477-1481.
95. Rosenauer, A., Raelson, J.V., Nervi, C., Eydoux, P., DeBlasio, A. and Miller, W.H., Jr. (1996) "Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines", Blood, 88, 2671-2682.
96. Nason Burchenal, K., Maerz, W., Albanell, J., Allopenna, J., Martin, P., Moore, M.A. and Dmitrovsky, E. (1997) "Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization", Differentiation, 61, 321-331.
97. Pandolfi, P.P. (2001) "Histone deacetylases and transcriptional therapy with their inhibitors", Cancer Chemother. Pharmacol., 48(Suppl. 1), S17-S19.
98. Chen, A., Licht, J.D., Wu, Y., Hellinger, N., Scher, W. and Waxman, S. (1994) "Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents", Blood, 84, 2122-2129.
99. Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., et al. (1999) "Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy", Leukemia, 13, 1316-1324.
100. Warrell, R.P.J., He, L.Z., Richon, V., Calleja, E. and Pandolfi, P.P. (1998) "Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase", J. Natl. Cancer Inst., 90, 1621-1625.
101. Novick, S., Camacho, L., Gallagher, R., Chanel, S., Ho, R., Tolentino, T., et al. (1999) "Initial clinical evaluation of 'transcription therapy' for cancer: All-trans retinoic acid plus phenylbutyrate", Blood, 94(Suppl. 1), 60a.
102. Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H. and Naoe, T. (2000) "Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17 in combination with all-trans retinoic acid", Br. J. Haematol., 108, 696-702.
103. He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R.P., Jr., Rifkind, R.A., et al. (2001) "Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia", J. Clin. Invest., 108, 1321-1330.
104. Licht, J.D., Chomienne, C., Goy, A., Chen, A., Scott, A.A., Head, D.R., et al. (1995) "Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)", Blood, 85, 1083-1094.
105. Koken, M.H., Daniel, M.T., Gianni, M., Zelent, A., Licht, J., Buzyn, A., et al. (1999) "Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient", Oncogene, 18, 1113-1118.
106. Rego, E.M., He, L.Z., Warrell, R.P., Jr., Wang, Z.G. and Pandolfi, P.P. (2000) "Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins", Proc. Natl. Acad. Sci. USA, 97, 10173-10178.
107. Yu, K.H., Weng, L.J., Fu, S., Piantadosi, S. and Gore, S.D. (1999) "Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid", Leukemia, 13, 1258-1265.
108. Taimi, M., Chen, Z.X. and Breitman, T.R. (1998) "Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide", Oncol. Res., 10, 75-84.
109. Calleja, E.M. and Warrell, R.P. (2000) "Differentiating Agents in Pediatric Malignancies: All-trans-Retinoic Acid and Arsenic in Acute Promyelocytic Leukemia", Curr. Oncol. Rep., 2, 519-523.
110. Raffoux, E., Rousselot, P., Poupon, J., Daniel, M.T., Cassinat, B., Delarue, R., et al. (2003) "Combined treatment with arsenic trioxide and all-trans-retinoic Acid in patients with relapsed acute promyelocytic leukemia", J. Clin. Oncol., 21, 2326-2334.
111. Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., et al. (1997) "Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients", Blood, 89, 3354-3360.
112. Shen, Y., Shen, Z.X., Yan, H., Chen, J., Zeng, X.Y., Li, J.M., et al. (2001) "Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage", Leukemia, 15, 735-741.
113. Jing, Y., Dai, J., Cahlmers-Redman, R.M.E., Tatton, W. and Waxman, S. (1999) "Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide dependent pathway", Blood, 94, 2102-2111.
114. Chen, G.Q., Shi, X.G., Tang, W., Xiong, S.M., Zhu, J., Cai, X., et al. (1997) "Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells", Blood, 89, 3345-3353.
115. Jing, Y., Wang, L., Xia, L., Chen, G.Q., Chen, Z., Miller, W.H. and Waxman, S. (2001) "Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo", Blood, 97, 264-269.
116. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. and de The, H. (2002) "How acute promyelocytic leukaemia revived arsenic", Nat. Rev. Cancer, 2, 705-713.
117. Cai, X., Shen, Y.-L., Zhu, Q., Jia, P.-M., Yu, Y., Zhou, L., et al. (2000) "Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia", Leukemia, 14, 262-270.
118. Lallemand-Breitenbach, V., Guillemin, M.C., Janin, A., Daniel, M.T., Degos, L., Kogan, S.C., et al. (1999) "Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia", J. Exp. Med., 189, 1043-1052.
119. Muto, A., Kizaki, M., Kawamura, C., Matsushita, H., Fukuchi, Y., Umezawa, A., et al. (2001) "A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF", Leukemia, 15, 1176-1184.
120. Kizaki, M., Mato, A., Kinjo, K., Ueno, H. and Ikeda, Y. (1998) "Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia", J. Natl. Cancer Inst., 90, 1906-1907.
121. Zhu, Q., Zhang, J.W., Zhu, H.Q., Shen, Y.L., Flexor, M., Jia, P.M., et al. (2002) "Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk", Blood, 99, 1014-1022.
122. Guillemin, M.C., Raffoux, E., Vitoux, D., Kogan, S., Soilihi, H., Lallemand-Breitenbach, V., et al. (2002) "In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia", J. Exp. Med., 196, 1371-1380.
123. Chen, G.Q., Zhou, L., Styblo, M., Walton, F., Jing, Y., Weinberg, R., et al. (2003) "Methylated trivalent arsenicals are potent apoptosis inducers in both acute promyelocytic leukemia and lymphoma cells", Cancer Res., 63, 1853-1859.
124. Dai, J., Weinberg, R.S., Waxman, S. and Jing, Y. (1999) "Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide trough modulation of the glutathione redox system", Blood, 93, 268-277.
125. Wang, Z.G., Rivi, R., Delva, L., Konig, A., Scheinberg, D.A., Gambacorti-Passerini, C., et al. (1998) "Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner", Blood, 92, 1497-1504.
126. Perkins, C., Kim, C.N., Fang, G. and Bhalla, K.N. (2000) "Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)", Blood, 95, 1014-1022.
127. La Rosee, P., Johnson, K., O'Dwyer, M.E. and Druker, B.J. (2002) "In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia", Exp. Hematol., 30, 729-737.
128. Puccetti, E., Guller, S., Orleth, A., Bruggenolte, N., Hoelzer, D., Ottmann, O.G. and Ruthardt, M. (2000) "BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity", Cancer Res., 60, 3409-3413.
129. El-Sabban, M.E., Nasr, R., Dbaibo, G., Hermine, O., Abboushi, N., Quignon, F., et al. (2000) "Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation", Blood, 96, 2849-2855.
130. Mahieux, R., Pise-Masison, C., Gessain, A., Brady, J.N., Olivier, R., Perret, E., et al. (2001) "Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage", Blood, 98, 3762-3769.
131. Look, A.T. (1997) "Oncogenic transcription factors in the human acute leukemias", Sciences, 278, 1059-1064.